[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Vaxine Pty Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":97},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100543389","phase-1-covid-19-and-influenza-oral-vaccine-study-100543389",false,"NCT06355232","Covid-19 and Influenza Oral Vaccine Study","A Binded, Randomised, Controlled Cross-over Trial to Assess the Safety and Efficacy of Mucosal Covid-19 and Influenza Vaccines","Inclusion Criteria:\n\n* Able to provide written informed consent\n* Males or females 18 years of age or older\n* Understand and are likely to comply with planned study procedures and be available for all study visits.\n* Do not plan to have a non-study COVID-19 or influenza vaccine within the next 6 months.\n\nExclusion Criteria:\n\n* Allergy to COVID-19 or seasonal influenza vaccine or one of its components e.g. polysorbate 80.\n* Have received a COVID-19 or influenza vaccine or an experimental agent within 30 days prior to the study vaccination or expect to receive another experimental agent or a COVID-19 or influenza vaccine during the trial reporting period.\n* Any serious medical, social or mental condition which, in the opinion of the investigator, would be detrimental to the subjects or the study.",true,"ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The purpose of the current study is to assess the effectiveness of protein-based COVID-19 or influenza vaccines when given individually or together via oral\u002F sublingual mucosal route instead of intramuscular delivery. The comparator will be a seasonal influenza vaccine which will also be administered with Advax-CpG adjuvant via the oral route. This study will use a cross-over design and everyone in the study will over a space of about 4 months receive both the COVID-19 and influenza vaccines.",[27,28],"covid19 Infection","Influenza, Human",[30,31,32,33,34,35,36,37],"covid-19","influenza","pandemic","mucosal","spikogen","advax","adjuvant","vaccine","RECRUITING","2025-09-16",{"date":41,"type":42},"2025-09-17","ACTUAL",{"date":44,"type":42},"2024-05-01",{"date":46,"type":21},"2026-12-31",{"name":48,"class":49},"Vaxine Pty Ltd","INDUSTRY",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":50},"100501267","phase-1-autologous-tumour-vaccine-trial-100501267","NCT05807035","Autologous Tumour Vaccine Trial","A Phase I Trial of Autologous Tumour Vaccine for Advanced Solid Cancers","Inclusion Criteria:\n\n* Subjects must have histologically or cytologically confirmed advanced solid cancers or hematological cancers (lymphomas only)\n* Subjects must have received at least one prior therapy for this disease, with the exception that subjects for whom no standard therapy options exist or who decline standard therapies can be considered for inclusion after discussions with the investigator team.\n* Performance status ≤ 2 (ECOG performance status)\n* Subjects or their parents if a child must have the ability to understand and the willingness to sign a written informed consent document.\n* If no suitable cancer tissue is already available to make the vaccine, to be enrolled in the trial participants must be willing to undergo surgery and\u002For fresh tumour biopsy to obtain tissue to allow the preparation of the vaccine and their primary care team needs to have agreed to perform these procedures for them to obtain tumour tissue. The trial team will provide advice on appropriate tissue collection and arrange transport and processing but are not responsible for arranging such surgery or paying for its cost.\n\nExclusion Criteria:\n\n* Subjects receiving any other investigational agents within the preceding 4 weeks.\n* Pregnant women because of the unknown risk of adverse events in the foetus secondary to treatment of the mother with ATV.\n* Any potential participant where suitable cancer tissue is not available for preparation of the vaccine\n* Any condition that the Investigator deems may make a potential participant unsuitable for entry into the trial.",{"count":59,"type":21},30,[24],"Phase 1 trial to evaluate the feasibility of preparation, safety, tolerability and response to a personalised autologous tumour vaccine (ATV) formulated with Advax adjuvant when administered to patients with advanced solid cancers either as monotherapy or in combination with other standard of care agents",[63],"Solid Tumor",[65,66,67,37,68],"cancer","tumor","immunotherapy","neoplasm",{"date":41,"type":42},{"date":71,"type":42},"2023-02-10",{"date":73,"type":21},"2028-02-10",{"name":48,"class":49},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":50},"100288750","phase-1-a-randomised-controlled-phase-1-study-of-vaccine-therapy-for-control-or-cure-of-chronic-hepatitis-b-virus-infection-100288750","NCT03038802","A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection","HBV003","Inclusion Criteria:\n\n* Male or female\n* 18 years of age or older\n* Current evidence of HBV chronic infection (with or without cirrhosis) as indicated by detection of HBsAg and\u002For Hepatitis B DNA (Subjects on current nucleoside therapy may have no detectable Hep B DNA)\n* If child bearing age, using contraception (barrier method, IUD or oral contraception)\n* Able to provide written informed consent\n* Willing and able to comply with the protocol for the duration of the study.\n\nExclusion Criteria:\n\n* Positive for antibody to hepatitis B core antigen (anti-HBc) IgM with negative results for the rest of the HBV markers, indicating acute infection,\n* Positive for anti-delta virus, or anti-hepatitis C virus or HIV\n* Childs Pugh Score for Cirrhosis Mortality of Child grade B or greater\n* Liver transaminases greater than 5 times the upper limit of normal\n* History of severe allergic reaction to hepatitis B vaccine.\n* Pregnancy or female of child-bearing age not using effective method of contraception.\n* Presence of any other organ-specific disease that in the opinion of the investigator may result in risk to the subject from involvement in the study\n* Current alcohol or drug abuse that in the opinion of the investigator may result in non-compliance.\n* Participation in another clinical trial with an investigational agent within 30 days preceding initiation of treatment",{"count":83,"type":21},40,[24,85],"PHASE2","This is a pilot study to determine the safety and efficacy of a novel adjuvanted hepatitis B virus (HBV) vaccine formulated as a potential therapeutic vaccine against chronic HBV infection. An ongoing human clinical trial of this HBV vaccine in a prophylactic setting has confirmed this vaccine to be more effective at inducing seroconversion as measured by development of Hepatitis B surface antibody (HBsAb) in poor responder subjects than the standard alum-adjuvanted HBV vaccine, providing promise that this new vaccine may also be able to induce HBV viral control and\u002For seroconversion in chronically infected subjects",[88],"Chronic Hepatitis b","NOT_YET_RECRUITING",{"date":91,"type":42},"2025-09-22",{"date":93,"type":21},"2026-03-01",{"date":95,"type":21},"2027-06-30",{"name":48,"class":49},""]